Skip to main content
SpringerLink
Log in

Anal Cancer: Background and Clinical Evidence

  • Chapter
  • First Online:
Radiation Therapy for Gastrointestinal Cancers

  • 1175 Accesses

Abstract

The incidence of squamous cell anal carcinoma is rising rapidly. The primary treatment for localized anal cancer is chemoradiation, with surgery used for salvage. This chapter reviews the epidemiology, prognostic factors, molecular biology, patterns of failure, and multidisciplinary treatment of anal cancer, along with a summary of key clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  2. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101:281–8.

    Article  PubMed  Google Scholar 

  3. Shridhar R, Shibata D, Chan E, Thomas CR. Anal cancer: current standards in care and recent changes in practice. CA Cancer J Clin. 2015;65:139–62.

    Article  PubMed  Google Scholar 

  4. Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol. 2013;31:1569–75.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270–80.

    Article  PubMed  Google Scholar 

  6. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337:1350–8.

    Article  CAS  PubMed  Google Scholar 

  7. Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist. 2007;12:524–34.

    Article  PubMed  Google Scholar 

  8. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10:1152–9.

    Article  CAS  PubMed  Google Scholar 

  9. Piketty C, Selinger-Leneman H, Bouvier AM, et al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol. 2012;30:4360–6.

    Article  PubMed  Google Scholar 

  10. Wells JS, Holstad MM, Thomas T, Bruner DW. An integrative review of guidelines for anal cancer screening in HIV-infected persons. AIDS Patient Care STDS. 2014;28:350–7.

    Article  PubMed  Google Scholar 

  11. Glynne-Jones R, Nilsson PJ, Aschele C, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111:330–9.

    Article  PubMed  Google Scholar 

  12. Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: a review. World J Gastrointest Surg. 2016;8:41–51.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576–85.

    Article  CAS  PubMed  Google Scholar 

  14. Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

  15. Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116:4007–13.

    Article  PubMed  Google Scholar 

  16. Glynne-Jones R, Kadalayil L, Meadows HM, et al. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. Ann Oncol. 2014;25:1616–22.

    Article  CAS  PubMed  Google Scholar 

  17. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30:4344–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Gunderson LL, Moughan J, Ajani JA, et al. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013;87:638–45.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68:794–800.

    Article  PubMed  Google Scholar 

  20. Rodel F, Wieland U, Fraunholz I, et al. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Int J Cancer. 2015;136:278–88.

    Article  PubMed  Google Scholar 

  21. Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, Hogdall E, Geertsen PF, Havsteen H. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol. 2014;32:1812–7.

    Article  PubMed  Google Scholar 

  22. Meulendijks D, Tomasoa NB, Dewit L, et al. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. Br J Cancer. 2015;112:1358–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Linam JM, Chand RR, Broudy VC, et al. Evaluation of the impact of HIV serostatus, tobacco smoking and CD4 counts on epidermoid anal cancer survival. Int J STD AIDS. 2012;23:77–82.

    Article  CAS  PubMed  Google Scholar 

  24. Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol. 2008;26:474–9.

    Article  PubMed  Google Scholar 

  25. Oehler-Janne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26:2550–7.

    Article  PubMed  Google Scholar 

  26. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009;124:2375–83.

    Article  CAS  PubMed  Google Scholar 

  27. Welton ML, Sharkey FE, Kahlenberg MS. The etiology and epidemiology of anal cancer. Surg Oncol Clin N Am. 2004;13:263–75.

    Article  PubMed  Google Scholar 

  28. Darragh TM, Colgan TJ, Thomas Cox J, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013;32:76–115.

    Article  PubMed  Google Scholar 

  29. Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg. 2005;92:1133–6.

    Article  CAS  PubMed  Google Scholar 

  30. National Cancer Institute: Surveillance E, and End Results Program. SEER Stat Fact Sheets: Anal Cancer. Available from URL: http://seer.cancer.gov/statfacts/html/anus.html. Accessed 20 Nov 2015.

  31. Leonard D, Beddy D, Dozois EJ. Neoplasms of anal canal and perianal skin. Clin Colon Rectal Surg. 2011;24:54–63.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9.

    CAS  PubMed  Google Scholar 

  33. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348:1049–54.

    Google Scholar 

  34. Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients. Dis Colon Rectum. 1992;35:422–9.

    Article  CAS  PubMed  Google Scholar 

  35. Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The Role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:3574–81.

    Article  PubMed  Google Scholar 

  36. Glynne-Jones R, Meadows H, Wan S, et al. EXTRA – a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008;72:119–26.

    Article  CAS  PubMed  Google Scholar 

  37. Meulendijks D, Dewit L, Tomasoa NB, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer. 2014;111:1726–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Thind G, Johal B, Follwell M, Kennecke HF. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. Radiat Oncol. 2014;9:124.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74:824–30.

    Article  PubMed  Google Scholar 

  40. Network. NCC. Anal Carcinoma (Version 1.2016). Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. Accessed 20 Nov 2015.

  41. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27–33.

    Article  CAS  PubMed  Google Scholar 

  42. Peiffert D, Tournier-Rangeard L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941–8.

    Article  CAS  PubMed  Google Scholar 

  43. John M, Pajak T, Flam M, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am. 1996;2:205–11.

    CAS  PubMed  Google Scholar 

  44. Chakravarthy AB, Catalano PJ, Martenson JA, et al. Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). Int J Radiat Oncol Biol Phys. 2011;81:e607–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Deniaud-Alexandre E, Touboul E, Tiret E, et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys. 2003;56:1259–73.

    Article  PubMed  Google Scholar 

  46. Rabbani AN, Zlotecki RA, Kirwan J, et al. Definitive radiotherapy for squamous cell carcinoma of the anal canal. Am J Clin Oncol. 2010;33:47–51.

    Article  PubMed  Google Scholar 

  47. Lestrade L, De Bari B, Pommier P, et al. Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective series. Strahlenther Onkol. 2014;190:546–54.

    Article  PubMed  Google Scholar 

  48. Moureau-Zabotto L, Ortholan C, Hannoun-Levi JM, et al. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study). Int J Radiat Oncol Biol Phys. 2013;85:e135–42.

    Article  PubMed  Google Scholar 

  49. Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014;5:11133–42.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Clinicaltrials.gov. Clinical Trial NCT02051868. Available from URL: https://clinicaltrials.gov/ct2/show/NCT02051868. Accessed 10 Mar 2016.

  51. Rogers JE, Crane CH, Das P, et al. Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2014;7:65–8.

    PubMed  PubMed Central  Google Scholar 

  52. Mullen JT, Rodriguez-Bigas MA, Chang GJ, et al. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol. 2007;14:478–83.

    Article  PubMed  Google Scholar 

  53. Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg. 2005;92:605–14.

    Article  CAS  PubMed  Google Scholar 

  54. Hoffman R, Welton ML, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44:127–31.

    Article  CAS  PubMed  Google Scholar 

  55. Balamucki CJ, Zlotecki RA, Rout WR, et al. Squamous cell carcinoma of the anal margin: the university of Florida experience. Am J Clin Oncol. 2011;34:406–10.

    Article  PubMed  Google Scholar 

  56. Steele SR, Varma MG, Melton GB, et al. Practice parameters for anal squamous neoplasms. Dis Colon Rectum. 2012;55:735–49.

    Article  PubMed  Google Scholar 

  57. Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51:1826–9.

    Article  CAS  PubMed  Google Scholar 

  58. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102:1123–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39.

    CAS  PubMed  Google Scholar 

  60. Doci R, Zucali R, La Monica G, et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol. 1996;14:3121–5.

    CAS  PubMed  Google Scholar 

  61. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–21.

    Article  CAS  PubMed  Google Scholar 

  62. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25:4581–6.

    Article  CAS  PubMed  Google Scholar 

  63. Kachnic LA, Tsai HK, Coen JJ, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012;82:153–8.

    Article  PubMed  Google Scholar 

  64. Mitchell MP, Abboud M, Eng C, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2014;37:461–6.

    Article  CAS  PubMed  Google Scholar 

  65. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63:354–61.

    Article  PubMed  Google Scholar 

  66. Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys. 2010;78:1413–9.

    Article  PubMed  Google Scholar 

  67. Bazan JG, Hara W, Hsu A, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011;117:3342–51.

    Article  PubMed  Google Scholar 

  68. Vieillot S, Fenoglietto P, Lemanski C, et al. IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center. Radiat Oncol. 2012;7:45.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Chuong MD, Freilich JM, Hoffe SE, et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2013;6:39–45.

    PubMed  PubMed Central  Google Scholar 

  70. Call JA, Prendergast BM, Jensen LG, et al. Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study. Am J Clin Oncol. 2016;39:8–12.

    Article  CAS  PubMed  Google Scholar 

  71. Boukhelif W, Ferri-Molina M, Mazeron R, et al. Interstitial pulsed-dose-rate brachytherapy for the treatment of squamous cell anal carcinoma: a retrospective single institution analysis. Brachytherapy. 2015;14:549–53.

    Article  CAS  PubMed  Google Scholar 

  72. Bruna A, Gastelblum P, Thomas L, et al. Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study. Radiother Oncol. 2006;79:75–9.

    Google Scholar 

  73. Falk AT, Claren A, Benezery K, et al. Interstitial high-dose rate brachytherapy as boost for anal canal cancer. Radiat Oncol. 2014;9:240.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Hwang JM, Rao AR, Cosmatos HA, et al. Treatment of T3 and T4 anal carcinoma with combined chemoradiation and interstitial 192Ir implantation: a 10-year experience. Brachytherapy. 2004;3:95–100.

    Article  PubMed  Google Scholar 

  75. Papillon J, Montbarbon JF, Gerard JP, Chassard JL, Ardiet JM. Interstitial curietherapy in the conservative treatment of anal and rectal cancers. Int J Radiat Oncol Biol Phys. 1989;17:1161–9.

    Article  CAS  PubMed  Google Scholar 

  76. Kapoor R, Khosla D, Shukla AK, et al. Dosimetric and clinical outcome in image-based high-dose-rate interstitial brachytherapy for anal cancer. Brachytherapy. 2014;13:388–93.

    Article  PubMed  Google Scholar 

  77. Oehler-Janne C, Seifert B, Lutolf UM, Studer G, Glanzmann C, Ciernik IF. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy. 2007;6:218–26.

    Article  PubMed  Google Scholar 

  78. Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol. 2008;87:383–90.

    Article  PubMed  Google Scholar 

  79. James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14:516–24.

    Article  CAS  PubMed  Google Scholar 

  80. Das P, Cantor SB, Parker CL, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer. 2010;116:822–9.

    Article  PubMed  Google Scholar 

  81. Han K, Cummings BJ, Lindsay P, et al. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Int J Radiat Oncol Biol Phys. 2014;90:587–94.

    Article  PubMed  Google Scholar 

  82. Tang Y, Crane CH, Eng C, et al. Quality of life after intensity-modulated radiation therapy for anal cancer. J Radiat Oncol. 2015;4:291–8.

    Article  Google Scholar 

  83. Fakhrian K, Sauer T, Dinkel A, et al. Chronic adverse events and quality of life after radiochemotherapy in anal cancer patients. A single institution experience and review of the literature. Strahlenther Onkol. 2013;189:486–94.

    Article  CAS  PubMed  Google Scholar 

  84. Allal AS, Sprangers MA, Laurencet F, Reymond MA, Kurtz JM. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer. 1999;80:1588–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Law E, Kelvin JF, Thom B, et al. Prospective study of vaginal dilator use adherence and efficacy following radiotherapy. Radiother Oncol. 2015;116:149–55.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Son CH, Law E, Oh JH, et al. Dosimetric predictors of radiation-induced vaginal stenosis after pelvic radiation therapy for rectal and anal cancer. Int J Radiat Oncol Biol Phys. 2015;92:548–54.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Baxter NN, Habermann EB, Tepper JE, Durham SB, Virnig BA. Risk of pelvic fractures in older women following pelvic irradiation. JAMA. 2005;294:2587–93.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Eleanor Osborne MD & Prajnan Das MD, MS, MPH

  2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Christopher Crane MD

Authors
  1. Eleanor Osborne MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher Crane MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prajnan Das MD, MS, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prajnan Das MD, MS, MPH .

Editor information

Editors and Affiliations

  1. Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Theodore Hong

  2. The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Prajnan Das

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Osborne, E., Crane, C., Das, P. (2017). Anal Cancer: Background and Clinical Evidence. In: Hong, T., Das, P. (eds) Radiation Therapy for Gastrointestinal Cancers. Springer, Cham. https://doi.org/10.1007/978-3-319-43115-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43115-4_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43113-0

  • Online ISBN: 978-3-319-43115-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation